Wolfe Research Begins Coverage on Sanofi (NASDAQ:SNY)

Analysts at Wolfe Research assumed coverage on shares of Sanofi (NASDAQ:SNY) in a report released on Friday, Briefing.com reports. The firm set a “peer perform” rating on the stock.

Other research analysts have also recently issued reports about the stock. Royal Bank Of Canada began coverage on shares of Sanofi in a report on Tuesday, September 8th. They set a “sector perform” rating for the company. Morgan Stanley set a $49.00 price objective on shares of Sanofi in a research report on Wednesday, July 8th. HSBC reaffirmed a “buy” rating on shares of Sanofi in a research report on Thursday, September 10th. Weiss Ratings downgraded Sanofi from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, August 3rd. Finally, Wall Street Zen cut shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $49.50.

Sanofi Price Performance

SNY stock opened at $40.23 on Friday. The company has a quick ratio of 0.64, a current ratio of 0.99 and a debt-to-equity ratio of 0.21. The firm has a market cap of $97.53 billion, a price-to-earnings ratio of 21.06, a PEG ratio of 1.21 and a beta of 0.33. The company’s fifty day simple moving average is $43.05 and its 200 day simple moving average is $44.02. Sanofi has a 12-month low of $39.18 and a 12-month high of $52.68.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, July 30th. The company reported $2.41 earnings per share for the quarter. Sanofi had a return on equity of 14.19% and a net margin of 8.66%.The firm had revenue of $13.36 billion during the quarter. During the same period last year, the business posted $3.24 earnings per share. The business’s revenue was up 16.0% on a year-over-year basis. On average, analysts expect that Sanofi will post 5.07 earnings per share for the current year.

Hedge Funds Weigh In On Sanofi

Several hedge funds and other institutional investors have recently modified their holdings of the company. Allworth Financial LP grew its stake in shares of Sanofi by 2.7% during the 2nd quarter. Allworth Financial LP now owns 9,233 shares of the company’s stock valued at $394,000 after acquiring an additional 243 shares during the period. Cohen Investment Advisors LLC boosted its position in shares of Sanofi by 2.9% in the first quarter. Cohen Investment Advisors LLC now owns 9,480 shares of the company’s stock worth $457,000 after purchasing an additional 263 shares during the period. Twin City Private Wealth LLC increased its stake in shares of Sanofi by 2.5% in the fourth quarter. Twin City Private Wealth LLC now owns 12,159 shares of the company’s stock worth $589,000 after purchasing an additional 293 shares in the last quarter. Leonteq Securities AG raised its position in shares of Sanofi by 95.8% during the 1st quarter. Leonteq Securities AG now owns 607 shares of the company’s stock valued at $29,000 after purchasing an additional 297 shares during the period. Finally, Arkadios Wealth Advisors lifted its stake in shares of Sanofi by 0.9% during the 1st quarter. Arkadios Wealth Advisors now owns 36,146 shares of the company’s stock valued at $1,742,000 after buying an additional 315 shares in the last quarter. 14.03% of the stock is owned by institutional investors.

About Sanofi

Sanofi is a France-based global healthcare company that develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. Its portfolio focuses on areas including immunology, rare diseases, vaccines, diabetes and other chronic conditions, as well as specialized treatments for selected neurological and inflammatory disorders.

The company is known for products such as Dupixent, a biologic used to treat several inflammatory conditions, and a broad range of vaccines marketed through its Sanofi Pasteur business.